Turning Pennies into dollars: (OTC: HSXI), (NASDAQ: IPCM), (NASDAQ: NGSX).
Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559
For more info: http://hsxi.realpennies.com
HealthSonix, Inc. (OTC: HSXI) (FRANKFURT: H7S)(February 5, 2008) announced Tuesday that it has launched a dedicated web site for its ZingiberRx Joint and Muscle cream: www.zingiberRx.com ZingiberRx joint and muscle cream is fast acting, non-staining, fast absorbing, and deep penetrating. Unlike most over-the-counter topical ointments, ZingiberRx is not a counter-irritant and does not create a hot or a cold sensation when applied.
Medical research studies into the medicinal properties of various plants in the ginger (Zingiberaceae) family have isolated the Zingiber cassumunar and Zingiber officinale species for their anti-inflammatory, anti-allergic and pain relieving properties.
"The launch of this web site coincides with on going retail sampling and couponing programs being tested in major pharmacy chains." said Dieter Doederlein, Vice President Corporate Development of HealthSonix. "The response to this new pain relieving cream, the first of its kind with ginger, continues to be very positive. We continue being a best selling topical pain reliever at those locations. "
The Company is also launching a major online sales and marketing campaign with Google and Yahoo adwords and banner ads on websites that cater to the 50+ population segment: "This new marketing program has been designed to increase awareness and promote direct to consumer sales from our online store." added Doederlein.
HealthSonix, Inc. (OTC: HSXI) (FRANKFURT: H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company's patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
For more info: http://ipcm.realpennies.com
IPC The Hospitalist Company, Inc. (NASDAQ: IPCM)February 5, 2008), a leading provider of hospitalist services, announced Tuesday that it closed its previously announced initial public offering of 5,200,000 shares on January 30, 2008 and that the underwriters of the offering have exercised their over-allotment option and purchased 705,000 additional shares of common stock from the selling stockholders at the public offering price of $16.00 per share. Including the over-allotment, the Company and selling stockholders sold 5,905,000 shares in the offering for net proceeds of $84.5 million after deducting the underwriting discounts and commission and the estimated offering expenses. Excluding shares offered by selling stockholders, net proceeds to the company amounted to approximately $45.8 million after deducting the underwriting discounts and commission and the estimated offering expenses. Credit Suisse Securities (USA) LLC and Jefferies & Company, Inc. acted as joint bookrunners for the offering. Wachovia Capital Markets, LLC and William Blair & Company, L.L.C. acted as co-managers for the offering. This offering is made only by means of a prospectus, copies of which may be obtained from the Credit Suisse Prospectus Department, One Madison Avenue, New York, NY 10010, (800) 221-1037, or Jefferies & Company Prospectus Department, 520 Madison Avenue, New York, NY 10022, (888) 449-2342.
Founded in 1995, IPC The Hospitalist Company, Inc. is a leading provider of hospitalist services in the United States. IPC's physicians manage and coordinate the care of hospitalized patients and serve as the inpatient partner of primary care physicians and specialists. IPC assists hospitals and payors in improving quality of inpatient care, increasing operating efficiencies and reducing costs. The Company provides its hospitalists with the management systems, information technology, training and administrative support necessary to perform these services.
For more info: http://ngsx.realpennies.com
NeurogesX, Inc. (NASDAQ: NGSX)February 6, 2008), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced yesterday that Anthony DiTonno, Chief Executive Officer, is scheduled to participate in a workshop focused on pain management at the 10th Annual BIO CEO & Investor Conference in New York, NY on Monday, February 11, 2008. The workshop starts at 9:30 a.m. EST at The Waldorf-Astoria Hotel, Basildon Room, 3rd Floor, 301 Park Avenue, New York, NY 10022.
A live audio Web cast of the workshop can be accessed at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=28873&item_id=1476 798
NeurogesX (NASDAQ: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX- 4010 have been completed and have met their primary endpoints
Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html
Sponsored by: http://www.isthemarketopen.com
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
No comments:
Post a Comment